Table 2.
Overall survival at each additional 5 y after BMT, y | Entire cohort | Primary diagnosis | ||||||
---|---|---|---|---|---|---|---|---|
ALL | AML | HL | NHL | Neuroblastoma | Other malignant disease* | |||
N | % | % | % | % | % | % | % | |
2+ | 280 | 81.2 | 67.4 | 95.6 | 86.7 | 90.3 | 78.5 | 71.9 |
5+ | 207 | 90.9 | 89.7 | 95.4 | 88.7 | 96.3 | 89.4 | 88.4 |
10+ | 162 | 95.3 | 96.2 | 97.5 | 95.3 | 82.0 | 97.6 | 100.0 |
15+ | 196 | 99.3 | 100.0 | 100.0 | 96.6 | 100.0 | 100.0 | 100.0 |
Includes 25 Ewing sarcomas, 11 Wilms tumor, 9 CNS tumors, 4 desmoplastic small round cell tumors, 6 soft tissue sarcoma, 1 ovarian tumor, 1 hepatoblastoma, and 1 multiple myeloma.